Skip to main content

Table 1 Characteristics of included studies

From: Health-related quality of life among long-term (≥5 years) prostate cancer survivors by primary intervention: a systematic review

  At survey ≥5 years Mean/ Median (Range)a At diagnosisg
First Author/ Year, Country Study Design Sample
Size (n)
Intervention (%) Age at survey (years) Follow-up timef
(years)
Cancer Stage (%)
Berg, A/ 2007,
Norway [35]
Hospital-based observational prospective monocentric cohort study 64 EBRT (100) [+ADT (44.0)]e 66c
(48-81)
11
(10-16)
Localized PC (33.0)
Locally advanced PC (67.0)
Brundage, M/ 2015, UK and US [36] Hospital-based mulitcentric randomized controlled trial 85-111d 1. ADT (50.0)c
2. ADT + EBRT (50.0)c
69.7c
(65.5
−73.5)
(5-8) Locally advanced PC (100.0)
Donovan, J L / 2016, UK [37] Population-based multicentric randomized controlled trial 1413-1463d 1. AS (33.2)
2. RP (33.7)
3. EBRT (33.1)
62c (5-6) Localized PC (100.0)
Fransson, P/ 2008, Sweden [38] Hospital-based observational prospective monocentric cohort study 64 1. EBRT (42.2) + ADT (20.3)
2. Controls (57.8)
78.1
(62-87)
14.7
(13.5 – 16.4)
Localized PC (89.9)
Locally advanced PC (11.1)
Fransson, P/ 2009, Sweden [39] Hospital-based observational monocentric retrospective cohort study 54 1. EBRT (50.0)
2. WW (50.0)
78
(54 – 88)
9.6
(6.4-16.3)
Local PC (100.0)
Galbraith, M E/ 2005, US [40] Hospital-based observational prospective monocentric cohort study 137 1. WW (11.5)c
2. RP (21.4)c
3. EBRT – C (9.9)b,c
4. EBRT - PB (11.5)b,c
5. EBRT - MB (20.3)b,c
6. EBRT -LD (13.7)b,c
7. EBRT - HD (17)b,c
69.9c 5.5 No information
Giberti, C/ 2009, Italy [41] Hospital-based monocentric randomized controlled trial 174 1. RP (44.5)
2. BT (55.5)
65.3c
(56-74)c
5 Localized PC (100.0)
Johnstone, P A S/ 2000, US [42] Hospital based observational monocentric prospective cohort study 46 EBRT (100.0)
[+ ADT (43.5)]e
80
(62-90)
13.9
(10 - 23)
Localized PC
Locally advanced PC
Mols, F/ 2006,
Denmark [43]
Population-based observational retrospective cohort study 780 1. RP (32.9)
2. EBRT (41.4)
3. ADT (13.7)
4. EBRT (11.9)
75 (5-10) Localized PC (76.0)
Locally Advanced PC (18.0)
Unknown (6.0)
Namiki, S/ 2011,
Japan [44]
Hospital-based observational prospective monocentric cohort study 111 1. RP (43.2) + ADT (48)
2. EBRT (56.8) + ADT (100.0)
69.5c
(53 – 84)
5 Locally Advanced PC (100.0)
Namiki, S/ 2014,
Japan [45]
Hospital-based observational prospective monocentric cohort study 91 RP (100.0) 63.9c 8.5
(7.1 - 10.25)
Localized PC (94.5)
Locally Advanced PC (5.5)
Shinohara, N/ 2013, Japan [46] Hospital-based observational monocentric prospective cohort study 67 1. EBRT (32.4)
2. RP (67.6)
68c
(53-79)
5 Localized PC (93.4)
Locally Advanced PC (6.6)
Thong, M S/ 2010, Nether-lands [47] Population-based observational retrospective cohort study 142 1. AS (50.0) [+ ADT (2.8)/ +RP (1.4)/ + EBRT (7)/ + EBRT + ADT (1.4)]e
2. EBRT (50.0) + [RP (7)/ + ADT (2.8)/ + EBRT (1.4) + EBRT + ADT (1.4)]e
75.8 7.8 Localized PC (100.0)
  1. RP Radical Prostatectomy, EBRT External Beam Radiotherapy (refers to the external delivery of any type of radiation), BT Brachytherapy, WW Watchful Waiting, AS Active Surveillance, ADT Androgen Deprivation Therapy
  2. aMean/Median for total sample
  3. bEBRT-C — Conventional radiation; EBRT-HD — High-dose mixed-beam radiation; EBRT-LD — Low-dose mixed-beam radiation; EBRT-MB — Standard protocol/mixed-beam radiation; EBRT-PB — Proton beam radiation
  4. cSample size/Age at enrolment in study or randomization
  5. dSample sizes at different time points ≥ 5 years
  6. eSecondary intervention(s)
  7. fEither time since diagnosis or time since randomization
  8. gCategorization: local PC – T1 & T2, locally advanced PC T3 & T4